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Resveratrol increases life span in lower organisms by activating the NAD+-dependent 
histone deacetylase Sirt1. Studies by Lagouge et al. (2006) and Baur et al. (2006) now 
show that resveratrol promotes longevity and improves glucose homeostasis in mice by 
stimulating the Sirt1-mediated deacetylation of the transcriptional coactivator PGC-1α.During the 15th century, the Venetian 
nobleman Luigi Cornaro documented 
the beneficial effects of caloric restric-
tion (he survived to the age of 102) in 
a treatise entitled “On the Sober Life.” 
Everyone has a different measure of 
sobriety—Cornaro’s daily diet included 
14 oz. of red wine. Indeed, resveratrol, a 
polyphenolic flavonoid enriched in the 
skins of red grapes, has been shown 
to increase life span in lower organ-
isms by binding to and enhancing 
the activity of the nicotina-
mide adenine dinucleotide 
(NAD+)-dependent histone 
deacetylase Sirt1 (Blander 
and Guarente, 2004). First 
identified as a transcrip-
tional silencer in yeast, Sirt1 
modulates the activity of a 
number of transcriptional 
regulators in mammals, 
most notably PGC-1α, a 
nuclear hormone receptor 
coactivator that promotes 
mitochondrial biogenesis in 
skeletal muscle and brown 
adipose tissue (Figure 1). 
Two new studies by Auwerx 
(Lagouge et al., 2006) and 
Sinclair (Baur et al., 2006) 
demonstrate that resveratrol 
improves energy balance 
and increases mitochondrial 
function in mice by stimu-
lating the Sirt1-mediated 
deacetylation of PGC-1α. 
The results have important 
implications for the treat-
ment of type II diabetes 
and perhaps other diseases 
associated with aging.
Obesity is a major risk factor in the 
development of insulin resistance, 
which is characterized by reduced 
glucose utilization in skeletal muscle. 
Chronic hyperglycemia, a hallmark of 
insulin resistance in the diabetic state, 
increases the production of reactive 
oxygen species, promotes mitochon-
drial damage, and impairs oxygen 
consumption in peripheral tissues. 
During fasting and caloric restriction, 
by contrast, elevations in cellular NAD+ 
are thought to protect against oxida-
tive stress and to promote cell survival 
by stimulating Sirt1 activity.
Because it increases the affinity of 
Sirt1 for NAD+, resveratrol would be 
predicted to improve metabolic func-
tion in the setting of obesity, where 
cellular NAD+ levels are low. The Auw-
erx and Sinclair groups tested this 
idea on mice that were fed a high-fat 
diet, which commonly promotes insu-
lin resistance. Both groups saw ben-
eficial effects of resvera-
trol on circulating glucose 
and insulin levels; but the 
apparent mechanisms of 
insulin sensitization were 
quite different.
Using oral doses 10- to 
20-fold higher than the Sin-
clair group, Auwerx and 
colleagues found that short-
term (15 week) resveratrol 
treatment protected young 
(4- to 8-week-old) male mice 
against obesity induced by a 
high-fat diet (Lagouge et al., 
2006). Indeed, amounts of 
adipose tissue were signifi-
cantly reduced in these mice, 
due in part to increased fat 
burning by the mitochon-
dria-enriched brown adipose 
tissue. In keeping with the 
role of brown fat in adaptive 
thermogenesis, core body 
temperatures were elevated 
in resveratrol-treated mice 
following cold exposure. 
The health benefits here 
are uncertain, however, as 
increases in core body tem-
Figure 1. Resveratrol Stimulates the Sirt1-PGC-1α Pathway
Resveratrol improves insulin sensitivity in mice by stimulating mito-
chondrial function via the Sirt1-PGC-1α pathway. Under basal condi-
tions PGC-1α is heavily acetylated and inactivated by GCN5. Eleva-
tions in cellular NAD+ during fasting and in response to exercise trigger 
the Sirt1-mediated deacetylation of PGC-1α. Deacetylated PGC-1α 
stimulates genes for oxidative phosphorylation in part by functioning 
as a coactivator for nuclear respiratory factor-1 (NRF-1). Resveratrol 
increases Sirt1 activation under high-fat diet conditions by increasing 
the affinity of Sirt1 for NAD+ and for acetylated PGC-1α.Cell 127, December 15, 2006 ©2006 Elsevier Inc. 1091
perature are thought to correlate with 
a reduced life span (Conti et al., 2006). 
Rather, lowering core body tempera-
ture has been show to increase sur-
vival in mice. Although they gain more 
weight than wild-type animals, such 
“cool mice” are apparently protected 
from oxidative damage in peripheral 
tissues because of reduced energy 
expenditure.
In addition to its effects on adipos-
ity, resveratrol also improved muscle 
function; resveratrol-treated mice 
were less prone to exercise-induced 
fatigue due to an increase in the pro-
portion of slow-twitch/oxidative mus-
cle fibers relative to fast-twitch/gly-
colytic fibers. Consistent with these 
changes, resveratrol increased the 
expression of mitochondrial genes 
and genes involved in oxidative phos-
phorylation. This is an important find-
ing because expression of genes 
involved in oxidative phosphorylation 
is often reduced in skeletal muscle 
from individuals with type II diabe-
tes (Mootha et al., 2003; Patti et al., 
2003). But how does resveratrol stim-
ulate expression of these genes?
Enter PGC-1α, a nuclear hormone 
receptor coactivator previously shown 
to increase the proportion of slow-
twitch fibers to fast-twitch fibers and 
to increase mitochondrial biogenesis 
in both muscle and brown adipose 
tissue (Lin et al., 2005). Auwerx found 
that resveratrol increased PGC-1α 
activity in muscle by promoting its 
deacetylation by Sirt1 (Lagouge et 
al., 2006). Consistent with this idea, 
resveratrol had no effect on the 
expression of PGC-1α target genes in 
cells deficient in Sirt1 or in myotubes 
expressing a mutant PGC-1α protein 
that could not be acetylated.
Extending their studies to humans, 
the Auwerx group found that asymp-
tomatic offspring of type II diabetic 
patients with single nucleotide poly-
morphisms (SNPs) in the Sirt1 gene 
exhibit abnormal energy expenditure 
relative to controls (Lagouge et al., 
2006). The studies were performed 
on a relatively small patient popula-
tion; if confirmed in other groups, 
however, these SNPS may have prog-
nostic value in identifying individuals 
at higher risk of developing type II 1092 Cell 127, December 15, 2006 ©200diabetes. Taken together, these stud-
ies support the idea that resveratrol 
improves energy balance under con-
ditions of a high-fat diet by trigger-
ing the SirT1:PGC-1α pathway and 
thereby stimulating mitochondrial 
function.
Using an older (1-year-old) cohort 
of mice compared to the Auwerx 
study, the Sinclair group found that 
chronic (1+ years) treatment with 
resveratrol at one-tenth the dose of 
the Auwerx group not only improved 
insulin sensitivity but, remarkably, 
increased life span in mice fed a 
high-fat diet (Baur et al., 2006). As 
opposed to the Auwerx group, the 
Sinclair study observed no effect of 
resveratrol on weight gain, adipos-
ity, or core body temperature. Rather 
they found that resveratrol improved 
glucose and lipid metabolism spe-
cifically in liver. Perhaps the most 
striking observation was the ability 
of resveratrol to protect mice against 
development of hepatic steatosis 
or fatty liver, a condition commonly 
associated with obesity and insulin 
resistance. In contrast, the Auwerx 
group found no changes in liver his-
tology between resveratrol-treated 
and control groups, which might 
reflect the shorter time course of 
resveratrol treatment or the younger 
cohort of mice they employed.
Sinclair and colleagues also found 
that, at doses comparable to the Auw-
erx study, resveratrol administration 
increased amounts of deacetylated 
and therefore active PGC-1α in liver 
(Baur et al., 2006). However, the 
induction of PGC-1α by resveratrol in 
liver is difficult to reconcile with the 
fact that PGC-1α triggers the glu-
coneogenic program and increases 
hepatic glucose production follow-
ing its deacetylation by Sirt1 in fasted 
mice (Rodgers et al., 2005). Rather, 
Sinclair and colleagues attribute the 
lowering of glucose with resvera-
trol treatment to the activation of 
the stress- and energy-sensing Ser/
Thr kinase AMPK, a potent inhibi-
tor of gluconeogenesis. Because it 
increases fatty-acid oxidation through 
phosphorylation and inhibition of 
acetyl coA carboxylase (the rate-lim-
iting enzyme in fatty-acid synthesis), 6 Elsevier Inc.AMPK may also protect mice treated 
with resveratrol against development 
of a fatty liver. However, whether res-
veratrol increases AMPK activity via 
Sirt1 is unclear; other polyphenols, 
which are not known to activate Sirt1, 
are also capable of stimulating AMPK 
(Zang et al., 2006). Indeed, some of 
the insulin-sensitizing effects of res-
veratrol in the Auwerx study may also 
reflect AMPK activation.
What could explain the apparent 
differences between the two stud-
ies? Following oral administration, 
resveratrol is rapidly glucuronidated 
and presumably inactivated in the 
liver (Gescher and Steward, 2003). 
The 10- to 20-fold higher dose of 
resveratrol used in the Auwerx study 
may be sufficient to promote its 
accumulation and to trigger Sirt1 
activation in brown fat and muscle. 
As well, potential off-target effects 
of resveratrol on AMPK and other 
pathways may be more pronounced 
at these higher doses.
Age-specific effects may also fac-
tor in. Amounts of brown adipose 
tissue have been shown to decline 
with age in rodents (McDonald and 
Horwitz, 1999); and impairments in 
the function of brown adipose tis-
sue may explain why resveratrol did 
not increase core body temperature 
or protect older mice from obesity 
induced by a high-fat diet in the Sin-
clair study. Further work on mice with 
muscle- and liver-specific knockouts 
of Sirt1 and PGC-1α should reveal 
the extent to which resveratrol mod-
ulates energy homeostasis via these 
effectors.
Taken together, the two stud-
ies point to an interesting parallel 
between the AMPK and Sirt1 sign-
aling pathways. Both pathways are 
energy sensing (AMP and NAD+), are 
triggered in response to fasting, and 
are capable of extending life span. 
In mammals, AMPK and Sirt1 also 
increase insulin sensitivity by improv-
ing glucose utilization, apparently via 
a mechanism that is dependent on 
PGC-1α. Future biochemical studies 
may reveal the extent to which these 
two pathways converge on PGC-1α 
and perhaps other regulators of glu-
cose and lipid metabolism.
Whatever the result, the Auwerx and 
Sinclair papers have provided new 
insight into the remarkable effects of 
a natural compound on life span and 
metabolism in mammals. As we await 
the development of more potent res-
veratrol analogs, perhaps we are best 
advised to heed Cornaro's advice that 
“men should live up to the simplicity 
dictated by nature, which teaches us 
to be content with little….”
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